US senators have labeled "the hedge-fund model of drug pricing" employed by the likes of Turing Pharmaceuticals, formerly run by Martin Shkreli, as "predatory" and "immoral" in a newly released report on drug companies' price hikes.
A patented cancer drug priced at $129,269 for a year’s supply is the subject of a petition sent to the National Institute of Health and the Department of Defense by two advocacy groups requesting they exercise “march-in” rights to make it affordable.
For the first time, medical marijuana is allowed at a public school. However, the parents of a teenager with autism and epilepsy will continue their legal battle to ensure the school nurse can actually administer the federally prohibited treatment.
The Senate’s Special Committee on Aging wants to know more about how four drug manufacturers came to raise prices of their products. One of the companies, Turing Pharmaceutical, hiked the price of a rare pill by 5,000 percent.
That which makes cancer so deadly could also be the key to killing it: A new FDA-approved therapy exploits the process by which cancerous cells multiply and spread. By introducing a special virus, cancer cells die while normal cells get stronger.